Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rhys D O Jones

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
CPT: Pharmacometrics & Systems Pharmacology|September 20, 2019
Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and OpportunitiesErica L Bradshaw, Mary E Spilker, Richard Zang, et al.
Drug Discovery Today|June 4, 2013
Model-based drug discovery: implementation and impactSandra A G Visser, Malin Aurell, Rhys D O Jones, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 27, 2024
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expressionChristina Vasalou, Theresa A Proia, Laura Kazlauskas, et al.
Journal of Pharmaceutical Sciences|April 12, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approachRagini Vuppugalla, Punit Marathe, Handan He, et al.
Molecular Pharmaceutics|December 10, 2021
Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy OutcomesChristina Vasalou, Douglas Ferguson, Weimin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft ModelsAlwin G Schuller, Evan R Barry, Rhys D O Jones, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approachPatrick Poulin, Rhys D O Jones, Hannah M Jones, et al.
Journal of Medicinal Chemistry|September 12, 2018
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal TumorsJason G Kettle, Rana Anjum, Evan Barry, et al.
Molecular Cancer Therapeutics|July 18, 2013
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivoSarah A Loddick, Sarah J Ross, Andrew G Thomason, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancerRobert H Bradbury, David G Acton, Nicola L Broadbent, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
CPT: Pharmacometrics & Systems Pharmacology|September 20, 2019
Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and OpportunitiesErica L Bradshaw, Mary E Spilker, Richard Zang, et al.
Drug Discovery Today|June 4, 2013
Model-based drug discovery: implementation and impactSandra A G Visser, Malin Aurell, Rhys D O Jones, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 27, 2024
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expressionChristina Vasalou, Theresa A Proia, Laura Kazlauskas, et al.
Journal of Pharmaceutical Sciences|April 12, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approachRagini Vuppugalla, Punit Marathe, Handan He, et al.
Molecular Pharmaceutics|December 10, 2021
Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy OutcomesChristina Vasalou, Douglas Ferguson, Weimin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft ModelsAlwin G Schuller, Evan R Barry, Rhys D O Jones, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approachPatrick Poulin, Rhys D O Jones, Hannah M Jones, et al.
Journal of Medicinal Chemistry|September 12, 2018
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal TumorsJason G Kettle, Rana Anjum, Evan Barry, et al.
Molecular Cancer Therapeutics|July 18, 2013
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivoSarah A Loddick, Sarah J Ross, Andrew G Thomason, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancerRobert H Bradbury, David G Acton, Nicola L Broadbent, et al.
Pageof 2